JP2015524460A5 - - Google Patents

Info

Publication number

JP2015524460A5

JP2015524460A5 JP2015525873A JP2015525873A JP2015524460A5 JP 2015524460 A5 JP2015524460 A5 JP 2015524460A5 JP 2015525873 A JP2015525873 A JP 2015525873A JP 2015525873 A JP2015525873 A JP 2015525873A JP 2015524460 A5 JP2015524460 A5 JP 2015524460A5

Authority

JP

Japan

Prior art keywords

infection

administration

dab

animal

human

Prior art date

2013-08-07

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 208000015181 infectious disease Diseases 0.000 claims 10
• 229960004089 tigecycline Drugs 0.000 claims 6
• 241001465754 Metazoa Species 0.000 claims 5
• 201000010099 disease Diseases 0.000 claims 5
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
• 150000003839 salts Chemical class 0.000 claims 5
• FPZLLRFZJZRHSY-HJYUBDRYSA-N tigecycline Chemical compound C([C@H]1C2)C3=C(N(C)C)C=C(NC(=O)CNC(C)(C)C)C(O)=C3C(=O)C1=C(O)[C@@]1(O)[C@@H]2[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FPZLLRFZJZRHSY-HJYUBDRYSA-N 0.000 claims 5
• 239000008194 pharmaceutical composition Substances 0.000 claims 4
• 150000001875 compounds Chemical class 0.000 claims 3
• 239000000816 peptidomimetic Substances 0.000 claims 2
• NMOSDUUZQBQTSX-NZUANIILSA-N (3R,9S,12S,15S,18S,21S,24S,27R,30S,33S,36S,39S,42S,45S)-15,18,24,27,33-pentakis(2-aminoethyl)-30-(3-aminopropyl)-36-[(2S)-butan-2-yl]-42-[(1R)-1-hydroxyethyl]-9-(hydroxymethyl)-21-(1H-indol-2-ylmethyl)-39-(1H-indol-3-ylmethyl)-12-methyl-1,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazatricyclo[43.3.0.03,7]octatetracontane-2,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecone Chemical compound CC[C@H](C)[C@@H]1NC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)[C@@H](NC(=O)[C@@H]2CCCN2C(=O)[C@H]2CCCN2C(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CCN)NC(=O)[C@H](CCN)NC(=O)[C@H](Cc2cc3ccccc3[nH]2)NC(=O)[C@H](CCN)NC(=O)[C@@H](CCN)NC(=O)[C@H](CCCN)NC(=O)[C@H](CCN)NC1=O)[C@@H](C)O NMOSDUUZQBQTSX-NZUANIILSA-N 0.000 claims 1
• OGNSCSPNOLGXSM-GSVOUGTGSA-N D-2,4-diaminobutyric acid Chemical group NCC[C@@H](N)C(O)=O OGNSCSPNOLGXSM-GSVOUGTGSA-N 0.000 claims 1
• OGNSCSPNOLGXSM-VKHMYHEASA-N L-2,4-diaminobutyric acid Chemical group NCC[C@H](N)C(O)=O OGNSCSPNOLGXSM-VKHMYHEASA-N 0.000 claims 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 1
• 239000002775 capsule Substances 0.000 claims 1
• 239000003795 chemical substances by application Substances 0.000 claims 1
• 239000006071 cream Substances 0.000 claims 1
• 239000008298 dragée Substances 0.000 claims 1
• 239000003814 drug Substances 0.000 claims 1
• 239000000499 gel Substances 0.000 claims 1
• -1 glycylcycline compound Chemical class 0.000 claims 1
• 238000001802 infusion Methods 0.000 claims 1
• 238000002347 injection Methods 0.000 claims 1
• 239000007924 injection Substances 0.000 claims 1
• 239000007788 liquid Substances 0.000 claims 1
• 238000004519 manufacturing process Methods 0.000 claims 1
• 239000006199 nebulizer Substances 0.000 claims 1
• 239000002674 ointment Substances 0.000 claims 1
• 229960003104 ornithine Drugs 0.000 claims 1
• 239000011505 plaster Substances 0.000 claims 1
• 239000000843 powder Substances 0.000 claims 1
• 230000002685 pulmonary effect Effects 0.000 claims 1
• 239000002002 slurry Substances 0.000 claims 1
• 239000000243 solution Substances 0.000 claims 1
• 239000012453 solvate Substances 0.000 claims 1
• 239000007921 spray Substances 0.000 claims 1
• 239000000829 suppository Substances 0.000 claims 1
• 239000000725 suspension Substances 0.000 claims 1
• 239000006188 syrup Substances 0.000 claims 1
• 235000020357 syrup Nutrition 0.000 claims 1
• 239000003826 tablet Substances 0.000 claims 1
• 238000011200 topical administration Methods 0.000 claims 1